Page 141 - 2026 SMOG

LEVETIRACETAM (KEPPRA)
Class/Mechanism of Action
• Anticonvulsant
˚ Causes modulation of synaptic neurotransmitter release through binding to the synaptic
vesicle protein SV2A in the brain
Indications
• Labeled Indications
˚ Treatment of focal (partial) onset seizures
• Labeled Indications
˚ Traumatic brain injury, severe acute (short-term seizure prophylaxis); status epilepticus;
craniotomy, seizure prophylaxis; subarachnoid hemorrhage (short-term seizure prophylaxis)
Contraindications
• Hypersensitivity to Levetiracetam or any component of the formulation
Adverse Reactions/Precautions
• May cause CNS depression
• Dermatologic reactions, possibly severe (TEN, SJS, etc.)
• Hypertension has been reported in children <4 years
• Hematologic effects: decreases in red blood cell counts, hemoglobin, hematocrit, white blood
cell counts, and neutrophils, and increases in eosinophils have been observed
Dose/Administration
PEDIATRIC
ADULT
(Always reference Broselow Tape)
Traumatic Brain Injury (Severe Acute)/ Traumatic Brain Injury/Seizure Prophylaxis
Short Term Seizure Prophylaxis • IV
• IV ˚ 20–55mg/kg/day in divided doses
˚ Loading dose: 1500mg over 15min twice daily
˚ Maintenance dose: 1000mg over 15min
q12hr

2026 Standard Medical Operating Guidelines (SMOG) • 133